Literature DB >> 14578868

Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.

Koichi Watashi1, Makoto Hijikata, Masahiro Hosaka, Masashi Yamaji, Kunitada Shimotohno.   

Abstract

Persistent infection of hepatitis C virus (HCV) is a major cause of liver diseases such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Searching for a substance with anti-HCV potential, we examined the effects of a variety of compounds on HCV replication using a HCV subgenomic replicon cell culture system. Consequently, the immunosuppressant cyclosporin A (CsA) was found to have a suppressive effect on the HCV replicon RNA level and HCV protein expression in these cells. CsA also inhibited multiplication of the HCV genome in a cultured human hepatocyte cell line infected with HCV using HCV-positive plasma. This anti-HCV activity of CsA appeared to be independent of its immunosuppressive function. In conclusion, our results suggest that CsA may represent a new approach for the development of anti-HCV therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14578868     DOI: 10.1053/jhep.2003.50449

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  146 in total

Review 1.  New treatment strategies against hepatitis C viral infection.

Authors:  Marc Bilodeau; Daniel Lamarre
Journal:  Can J Gastroenterol       Date:  2006-11       Impact factor: 3.522

2.  NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon.

Authors:  Sue Ma; Joanna E Boerner; ChoiLai TiongYip; Beat Weidmann; Neil S Ryder; Michael P Cooreman; Kai Lin
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 3.  Chronic viral hepatitis in kidney transplantation.

Authors:  Janna Huskey; Alexander C Wiseman
Journal:  Nat Rev Nephrol       Date:  2011-02-01       Impact factor: 28.314

Review 4.  Identification of HIV inhibitors guided by free energy perturbation calculations.

Authors:  Orlando Acevedo; Zandrea Ambrose; Patrick T Flaherty; Hadega Aamer; Prashi Jain; Somisetti V Sambasivarao
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

5.  Cyclosporin A inhibits the replication of diverse coronaviruses.

Authors:  Adriaan H de Wilde; Jessika C Zevenhoven-Dobbe; Yvonne van der Meer; Volker Thiel; Krishna Narayanan; Shinji Makino; Eric J Snijder; Martijn J van Hemert
Journal:  J Gen Virol       Date:  2011-07-13       Impact factor: 3.891

Review 6.  Studying hepatitis C virus: making the best of a bad virus.

Authors:  Timothy L Tellinghuisen; Matthew J Evans; Thomas von Hahn; Shihyun You; Charles M Rice
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

7.  Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.

Authors:  Jan Paeshuyse; Inge Vliegen; Lotte Coelmont; Pieter Leyssen; Oriana Tabarrini; Piet Herdewijn; Harald Mittendorfer; Johnny Easmon; Violetta Cecchetti; Ralf Bartenschlager; Gerhard Puerstinger; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

Review 8.  Host-targeting agents in the treatment of hepatitis C: a beginning and an end?

Authors:  James M Baugh; Jose A Garcia-Rivera; Philippe A Gallay
Journal:  Antiviral Res       Date:  2013-09-30       Impact factor: 5.970

9.  Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro.

Authors:  Feng Yang; Jason M Robotham; Heather B Nelson; Andre Irsigler; Rachael Kenworthy; Hengli Tang
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

Review 10.  [Progress in immunosuppression].

Authors:  C P Strassburg; M J Bahr; T Becker; J Klempnauer; M P Manns
Journal:  Chirurg       Date:  2008-02       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.